Cargando…

Structural basis of HCoV-19 fusion core and an effective inhibition peptide against virus entry

Detalles Bibliográficos
Autores principales:	Sun, Huan, Li, Yan, Liu, Peipei, Qiao, Chengpeng, Wang, Xiaomin, Wu, Lianao, Liu, Kefang, Hu, Yu, Su, Chao, Tan, Shuguang, Zou, Shumei, Wu, Guizhen, Yan, Jinghua, Gao, George Fu, Qi, Jianxun, Wang, Qihui
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Taylor & Francis 2020
Materias:	Letter
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7448930/ https://www.ncbi.nlm.nih.gov/pubmed/32482145 http://dx.doi.org/10.1080/22221751.2020.1770631

Ejemplares similares

Origins of HIV, HCoV-HKU1, SFTSV, and MERS-CoV and Beyond
por: Liu, Wenli, et al.
Publicado: (2022)

Structural characterization of the HCoV-229E fusion core
por: Zhang, Wei, et al.
Publicado: (2018)

Characterization of HCoV-229E fusion core: Implications for structure basis of coronavirus membrane fusion
por: Liu, Cheng, et al.
Publicado: (2006)

Coronavirus humains (HCoV)
por: Vabret, A., et al.
Publicado: (2009)

Adaptation of the endemic coronaviruses HCoV-OC43 and HCoV-229E to the human host
por: Forni, Diego, et al.
Publicado: (2021)

Human Coronaviruses HCoV-NL63 and HCoV-HKU1 in Hospitalized Children with Acute Respiratory Infections in Beijing, China
por: Cui, Li-Jin, et al.
Publicado: (2011)

Titration of Human Coronaviruses, HCoV-229E and HCoV-OC43, by an Indirect Immunoperoxidase Assay
por: Lambert, Francine, et al.
Publicado: (2007)

Seasonality and immunity to laboratory-confirmed seasonal coronaviruses (HCoV-NL63, HCoV-OC43, and HCoV-229E): results from the Flu Watch cohort study
por: Aldridge, Robert W., et al.
Publicado: (2020)

Heparan Sulfate and Enoxaparin Interact at the Interface of the Spike Protein of HCoV-229E but Not with HCoV-OC43
por: Fuochi, Virginia, et al.
Publicado: (2023)

Genetic tracing of HCoV-19 for the re-emerging outbreak of COVID-19 in Beijing, China
por: Yang, Jing, et al.
Publicado: (2020)

Mouse models susceptible to HCoV-229E and HCoV-NL63 and cross protection from challenge with SARS-CoV-2
por: Liu, Donglan, et al.
Publicado: (2023)

Seroconversion to HCoV-NL63 in Rhesus Macaques
por: Dijkman, Ronald, et al.
Publicado: (2009)

Understanding Human Coronavirus HCoV-NL63
por: Abdul-Rasool, Sahar, et al.
Publicado: (2010)

Novel polymeric inhibitors of HCoV-NL63
por: Milewska, Aleksandra, et al.
Publicado: (2013)

HCoV-229E Infects and Activates Monocytes
por: Desforges, Marc, et al.
Publicado: (2006)

SARS-CoV, But not HCoV-NL63, Utilizes Cathepsins to Infect Cells: Viral Entry
por: Huang, I-Chueh, et al.
Publicado: (2006)

Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2012)

Structural basis of main proteases of HCoV-229E bound to inhibitor PF-07304814 and PF-07321332
por: Zhou, Yanru, et al.
Publicado: (2023)

Structural and Functional Basis of SARS-CoV-2 Entry by Using Human ACE2
por: Wang, Qihui, et al.
Publicado: (2020)

Baculovirus expression of HCoV-OC43 nucleocapsid protein and development of a Western blot assay for detection of human antibodies against HCoV-OC43
por: Mourez, Thomas, et al.
Publicado: (2007)

Montelukast Inhibits HCoV-OC43 Infection as a Viral Inactivator
por: Chen, Yongkang, et al.
Publicado: (2022)

HCoV-Oc43–Induced Apoptosis of Murine Neuronal Cells
por: Jacomy, Hélène, et al.
Publicado: (2006)

HCoV-OC43–Induced Encephalitis is in Part Immune-Mediated
por: Butler, Noah, et al.
Publicado: (2006)

Epidemiology of respiratory coronaviruses (HCoV) in a Dutch university hospital
por: Niesters, H.G.M., et al.
Publicado: (2006)

Improving human coronavirus OC43 (HCoV-OC43) research comparability in studies using HCoV-OC43 as a surrogate for SARS-CoV-2
por: Schirtzinger, Erin E., et al.
Publicado: (2022)

Pan-Coronavirus CRISPR-CasRx Effector System Significantly Reduces Viable Titer in HCoV-OC43, HCoV-229E, and SARS-CoV-2
por: Mayes, Cathryn M., et al.
Publicado: (2023)

The human coronavirus HCoV-229E S-protein structure and receptor binding
por: Li, Zhijie, et al.
Publicado: (2019)

Inhibition of HCoV-NL63 infection at early stages of the replication cycle
por: van der Hoek, L., et al.
Publicado: (2006)

Prevalence of Neutralising Antibodies to HCoV-NL63 in Healthy Adults in Australia
por: Lynch, Sean A., et al.
Publicado: (2021)

Antigenic mapping reveals sites of vulnerability on α-HCoV spike protein
por: Xiang, Jiangchao, et al.
Publicado: (2022)

SNAP@CQD as a promising therapeutic vehicle against HCoVs: An overview
por: Chatterjee, Satyaki, et al.
Publicado: (2023)

Less severe course of COVID-19 is associated with elevated levels of antibodies against seasonal human coronaviruses OC43 and HKU1 (HCoV OC43, HCoV HKU1)
por: Dugas, Martin, et al.
Publicado: (2021)

HCoV- and SARS-CoV-2 Cross-Reactive T Cells in CVID Patients
por: Steiner, Sophie, et al.
Publicado: (2020)

The human coronaviruses (HCoVs) and the molecular mechanisms of SARS-CoV-2 infection
por: Santacroce, Luigi, et al.
Publicado: (2020)

Inhibition of coronavirus HCoV-OC43 by targeting the eIF4F complex
por: Feng, Yongmei, et al.
Publicado: (2022)

Inhibition by components of Glycyrrhiza uralensis of 3CLpro and HCoV-OC43 proliferation
por: Kim, Jang Hoon, et al.
Publicado: (2023)

Corrigendum to ’Replication of human coronaviruses SARS-CoV, HCoV-NL63 and HCoV-229E is inhibited by the drug FK506’ Virus Research (2012) 165/1 [112-117]: Corrigendum
por: Carbajo-Lozoya, Javier, et al.
Publicado: (2022)

Épidémiologie des infections à coronavirus HCoV-HKU1 à Marseille, France
por: Ninove, L., et al.
Publicado: (2020)

anti-HCoV: A web resource to collect natural compounds against human coronaviruses
por: Monticolo, Francesco, et al.
Publicado: (2020)

Erythromycin Estolate Is a Potent Inhibitor Against HCoV-OC43 by Directly Inactivating the Virus Particle
por: Wang, Xiaohuan, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_rl2irdp99rcicrvsi19mhobkoc